Shares of DaVita Inc. (NYSE:DVA – Get Free Report) hit a new 52-week high during trading on Monday . The company traded as high as $236.51 and last traded at $234.7880, with a volume of 830603 shares traded. The stock had previously closed at $234.91.
Analyst Ratings Changes
A number of analysts have recently issued reports on the company. UBS Group boosted their price objective on DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft upgraded shares of DaVita from a “hold” rating to a “buy” rating and lifted their price target for the stock from $126.00 to $220.00 in a research note on Wednesday, May 6th. Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a research note on Monday, June 8th. Barclays raised their price objective on shares of DaVita from $158.00 to $194.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Finally, Truist Financial lifted their target price on shares of DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $199.17.
View Our Latest Analysis on DVA
DaVita Trading Down 0.6%
DaVita (NYSE:DVA – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. The firm had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company’s revenue for the quarter was up 6.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, analysts predict that DaVita Inc. will post 15.07 EPS for the current fiscal year.
Insider Activity at DaVita
In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.50% of the stock is owned by insiders.
Institutional Investors Weigh In On DaVita
A number of hedge funds have recently added to or reduced their stakes in DVA. Chapin Davis Inc. bought a new position in shares of DaVita in the second quarter worth about $1,012,000. GAMMA Investing LLC increased its holdings in shares of DaVita by 11.2% in the second quarter. GAMMA Investing LLC now owns 3,100 shares of the company’s stock valued at $690,000 after purchasing an additional 311 shares in the last quarter. Value Investment Professionals LLC raised its position in DaVita by 2.0% in the 2nd quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock worth $556,000 after purchasing an additional 50 shares during the last quarter. CX Institutional lifted its holdings in DaVita by 7.7% during the 2nd quarter. CX Institutional now owns 2,480 shares of the company’s stock worth $552,000 after buying an additional 178 shares in the last quarter. Finally, Cozad Asset Management Inc. acquired a new position in DaVita during the 1st quarter worth $212,000. Institutional investors own 90.12% of the company’s stock.
About DaVita
DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.
Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.
Featured Stories
- Five stocks we like better than DaVita
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
